SEC Form 4 · accession 0001209191-17-001651
CRESCENT BIOPHARMA, INC. · CBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen M. Thackray
Officer — SVP Clinical Development, CMO
Period of report
Jan 4, 2017
Accepted (ET)
Jan 5, 2017 · 8:51 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001253689
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $6.33 | Jan 4, 2017 | A | 75,000 | A | — | Jan 3, 2027 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1One-fourth of the shares underlying this option vest on January 4, 2018 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the reporting person's continuous service as of each such vesting date.